摘要
目的探讨原发性肝癌(HCC)患者索拉非尼联合经肝动脉化疗栓塞(TACE)术治疗的有效性及对患者低氧诱导因子-1α(HIF-α)、白介素细胞-10(IL-10)、干扰素γ(IFN-γ)及血管内皮(细胞)生长因子(VEGF)水平的影响。方法选取120例HCC患者,依据不同治疗方法分两组,对照组应用TACE术治疗,研究组联合应用索拉非尼。观察比较两组治疗后的实体瘤相关结局指标:疾病控制率(DCR)及客观缓解率(ORR)差异;两组的相关不良反应情况;两组治疗前、治疗后相关指标因子:低氧诱导因子-1α(HIF-α)、白介素细胞-10(IL-10)、干扰素γ(IFN-γ)及血管内皮(细胞)生长因子(VEGF)水平差异及变化情况。结果研究组DCR水平及ORR水平均比对照组高(P均<0.05)。研究组骨髓抑制发生率与对照组相比无显著差异(P>0.05),研究组高血压、胃肠道反应及皮肤黏膜反应发生率比对照组高(P<0.05),但是均为可耐受的Ⅰ级~Ⅱ级轻度不良反应。研究组治疗后相关指标因子:HIF-α、IL-10及VEGF水平均比对照组更低(P<0.05),研究组IFN-γ水平高于对照组(P<0.05)。结论给予HCC患者在TACE术的基础上联合使用索拉非尼治疗,可使得疗效显著提高,降低HIF-α、IL-10及VEGF水平,提高IFN-γ水平。
Objective To investigate the efficacy of sorafenib combined with transcatheter arterial chemoembolization(TACE)in patients with primary liver cancer(HCC)and its effects on the levels of hypoxia inducible factor-1α(HIF-α),interleukin-10(IL-10),interferon gamma(IFN-γ)and vascular endothelial growth factor(VEGF)in patients with primary liver cancer(HCC).Methods 120 patients with HCC diagnosed and treated were selected and divided into 2 groups according to different treatment methods.The control group was treated with TACE,and the study group was treated with sorafenib.To observe and compare the 2 groups after treatment of solid tumor related outcome indicators,disease control rate(DCR)and objective remission rate(ORR);f related adverse reactions;related index factors before and after treatment,hypoxia inducible factor-1α(HIF-α),interleukin-10(IL-10),interferon gamma(IFN-γ)and vascular endothelial growth factor(VEGF)levels differences and changes.Results DCR level and ORR level were higher than those in the control group(P<0.05).There was no significant difference in the incidence of myelosuppression between the study group and the control group(P>0.05).The incidence of hypertension,gastrointestinal reaction and skin mucosal reaction in the study group was higher than that in the control group(P<0.05),but they were tolerable grade I~II mild adverse reactions.After treatment,the levels of HIF-α,IL-10 and VEGF in the study group were lower than those in the control group(P<0.05),and the IFN-γlevel in the study group was higher than that in the control group(P<0.05).Conclusion The combination of sorafenib and TACE can significantly improve the efficacy of HCC,reduce the levels of HIF-α,IL-10 and VEGF,and increase the level of IFN-γ.
作者
孙志刚
曾宝珠
焦勤书
张喜峰
王伟峰
张志华
杜敏
SUN Zhigang;ZENG Baozhu;JIAO Qinshu(Zhengzhou Traditional Chinese Medicine Hospital,Zhengzhou,450000)
出处
《实用癌症杂志》
2021年第5期810-813,共4页
The Practical Journal of Cancer
